Antitumor agent

Details Antitumor agent Antitumor agent

2008-01-01

2008-01-01

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S317000

Reexamination Certificate

active

07314862

ABSTRACT:
The present invention relates to an antitumor agent containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination. This combination has been found to exhibit a synergistic anticancer or antitumor effect compared to administration of either the histone deacetylase alone or the topoisomerase II inhibitor alone. Thus, this combination provides a tumor or cancer treatment with fewer side effects since a lower dosage of both ingedients may be administered.

REFERENCES:
patent: 486379 (1892-11-01), King
patent: 574455 (1897-01-01), Schrantz
patent: 3997633 (1976-12-01), Leva et al.
patent: 4348388 (1982-09-01), Garland et al.
patent: 4401592 (1983-08-01), Yoshikumi et al.
patent: 4950755 (1990-08-01), Witiak et al.
patent: 4977138 (1990-12-01), Okuhara et al.
patent: 5091373 (1992-02-01), Gatti et al.
patent: 5242901 (1993-09-01), Speyer et al.
patent: 5514664 (1996-05-01), Ulrich
patent: 5620961 (1997-04-01), Markovic et al.
patent: 5780054 (1998-07-01), Tardi et al.
patent: 5919816 (1999-07-01), Hausheer et al.
patent: 6020373 (2000-02-01), Schellenberg et al.
patent: 6197809 (2001-03-01), Strelchenok
patent: 6286513 (2001-09-01), Au et al.
patent: 6348209 (2002-02-01), Placke et al.
patent: 6403555 (2002-06-01), Skov
patent: 6419900 (2002-07-01), Placke et al.
patent: 6419901 (2002-07-01), Placke et al.
patent: 6451784 (2002-09-01), Placke et al.
patent: 6471943 (2002-10-01), Placke et al.
patent: 6541661 (2003-04-01), Delorme et al.
patent: 6800639 (2004-10-01), Giles et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 7056883 (2006-06-01), Ito et al.
patent: 7056884 (2006-06-01), Nakajima et al.
patent: 2001/0018425 (2001-08-01), Strelchenok
patent: 2001/0036444 (2001-11-01), Placke et al.
patent: 2001/0038826 (2001-11-01), Placke et al.
patent: 2001/0038827 (2001-11-01), Placke et al.
patent: 2002/0028237 (2002-03-01), Colbern et al.
patent: 2002/0049169 (2002-04-01), Minotti et al.
patent: 2002/0049170 (2002-04-01), Minotti et al.
patent: 2002/0131995 (2002-09-01), Szoka, Jr.
patent: 2002/0155066 (2002-10-01), Placke et al.
patent: 2002/0156023 (2002-10-01), Walling et al.
patent: 2002/0192814 (2002-12-01), Tamarkin et al.
patent: 2003/0053983 (2003-03-01), Tamarkin et al.
patent: 2003/0083316 (2003-05-01), Giles et al.
patent: 2003/0099960 (2003-05-01), Ratain et al.
patent: 2003/0144570 (2003-07-01), Hunter et al.
patent: 2003/0166602 (2003-09-01), Szoka, Jr.
patent: 2004/0014694 (2004-01-01), Chakroun
patent: 2004/0053820 (2004-03-01), Nakajima et al.
patent: 2004/0077561 (2004-04-01), Minotti et al.
patent: 2004/0136905 (2004-07-01), Kent et al.
patent: 2004/0152632 (2004-08-01), Feingold
patent: 2005/0004081 (2005-01-01), Giles et al.
patent: 2005/0070467 (2005-03-01), Naoe et al.
patent: 2005/0187149 (2005-08-01), Naoe et al.
patent: 2005/0191713 (2005-09-01), Sasakawa et al.
patent: 2005/0222013 (2005-10-01), Jung et al.
patent: 2006/0135413 (2006-06-01), Naoe et al.
patent: 2006/0223747 (2006-10-01), Ito et al.
patent: 1 302 476 (2003-04-01), None
patent: 1426054 (2004-06-01), None
patent: WO 02/06307 (2002-01-01), None
patent: WO 02/085400 (2002-10-01), None
patent: WO 03015810 (2003-02-01), None
patent: WO 2004/064727 (2004-08-01), None
patent: WO 2004/103358 (2004-12-01), None
patent: WO 2004/103369 (2004-12-01), None
R. Furumai, et al. Cancer Res. (2002), pp. 4916-4921.
H.J. Kwon, et al. Int. J. Cancer (2002), pp. 290-296.
W.-G. Zhu and G.A. Otterson. Curr. Med. Chem. (2003), pp. 187-199.
M. Murata, et al. Jpn. J. Cancer. Res. (2000), pp. 1154-1160.
Y. Sasakawa, et al. Cancer Letters. (2003), pp. 161-168.
Y. Sasakawa, et al. Biochem. Pharm. (2003), pp. 897-906.
E. Swain. Pharmaceutical and Medical Packagind New Aug. 1999, 4 pages.
C. Monneret. Eur. J. Med. Chem. (2001), pp. 483-493.
M. Jung. Curr. Med. Chem. (2001), pp. 1505-1511.
G. Ranjgolikar, et al. Breast Cancer Res. Treat. (1998), pp. 29-38.
Hidenori Nakajima, et al., “FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor”, Experimental Cell Research, vol. 241, 1998, pp. 126-133.
Khan W. Li, et al., “Total Synthesis of the Antitumor Depsipeptide FR-901-228”, J. Am. Chem. Soc., vol. 118, No. 30, 1996, pp. 7237-7238.
Yasuhiko Kano, et al., “The combined effects of histone deacetylase inhibitor FK228 and other anticancer agents—in vitro consideration”, The Japanese Journal of Clinical Hematology, vol. 43, No. 8, Aug. 30, 2002, p. 116 (with English abstract).
Hirotsugu Ueda, et al., “FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium Violaceum No. 968”, The Journal of Antibiotics, vol. 47, No. 3, 1994, pp. 315-323.
Hiroshi Kosugi, et al., “In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi-scid/scid Mice”, Jpn. J. Cancer Res., vol. 92, May 2001, pp. 529-536.
Richard L. Piekarz, et al., “Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report”, BLOOD, vol. 98, No. 9, Nov. 1, 2001, pp. 2865-2868.
Yuka Sasakawa, et al., “Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo”, Biochemical Pharmacology, vol. 64, 2002, pp. 1079-1090.
Myoung Sook Kim, et al., “Inhibition of histone deacetylase increases topoisomerase inhibitors efficiency in cells clinically resistant to Top2 inhibitors”, Proceedings of the American Association for Cancer Research, vol. 43, XP-001205058, Mar. 2002, pp. 510-511.
Mikhail V. Blagosklonny, et al., “Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs”, The Journal of Clinical Investigation, Feb. 2000, vol. 105, No. 4, pp. 533-539.
U.S. Appl. No. 10/546,285, filed May 31, 2006, Sasakawa, et al.

Affiliated with

Also associated with

Rating

Antitumor agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antitumor agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2805517